STAT+: FDA advisory panel endorses Moderna mRNA flu vaccine that was subject of controversy

An FDA advisory panel has officially recommended the approval of Moderna's mRNA-based seasonal flu vaccine. This endorsement specifically targets the use of the shot for older adults. The recommendation comes after the vaccine became the subject of controversy earlier this year. The panel's decision supports the deployment of this mRNA technology for seasonal influenza prevention, marking a significant step forward for Moderna's vaccine development despite the earlier disputes surrounding the product's initial reception.